CIPLA Stock Overview
Engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CIPLA from our risk checks.
Cipla Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹19.60 |
| 52 Week High | ₹0 |
| 52 Week Low | ₹0 |
| Beta | 0.36 |
| 11 Month Change | 4.26% |
| 3 Month Change | 10.73% |
| 1 Year Change | 40.00% |
| 33 Year Change | 49.62% |
| 5 Year Change | 237.93% |
| Change since IPO | 230.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| CIPLA | LU Pharmaceuticals | LU Market | |
|---|---|---|---|
| 7D | -1.5% | 0% | 0% |
| 1Y | 40.0% | 0% | 0% |
Return vs Industry: CIPLA exceeded the Luxembourg Pharmaceuticals industry which returned 13% over the past year.
Return vs Market: CIPLA exceeded the Luxembourg Market which returned 4.4% over the past year.
Price Volatility
| CIPLA volatility | |
|---|---|
| CIPLA Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in LU Market | 0% |
| 10% least volatile stocks in LU Market | 0% |
Stable Share Price: CIPLA has not had significant price volatility in the past 3 months.
Volatility Over Time: CIPLA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1935 | 27,764 | Umang Vohra | www.cipla.com |
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry.
Cipla Limited Fundamentals Summary
| CIPLA fundamental statistics | |
|---|---|
| Market cap | US$15.82b |
| Earnings (TTM) | US$514.72m |
| Revenue (TTM) | US$3.10b |
30.7x
P/E Ratio5.1x
P/S RatioIs CIPLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CIPLA income statement (TTM) | |
|---|---|
| Revenue | ₹258.92b |
| Cost of Revenue | ₹90.00b |
| Gross Profit | ₹168.92b |
| Other Expenses | ₹125.89b |
| Earnings | ₹43.03b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 53.29 |
| Gross Margin | 65.24% |
| Net Profit Margin | 16.62% |
| Debt/Equity Ratio | 2.1% |
How did CIPLA perform over the long term?
See historical performance and comparison